DynaPro Plate Reader Optimizes Screening Process for Biotherapeutic Candidates and Formulations
Wyatt Technology Corporation highlights a study recently authored by Martin Skov Neergaard from the Faculty of Health and Medical Sciences at the University of Copenhagen, “Protein-Protein Interactions Investigated by DLS: Determination at High and Low Protein Concentration.” This article outlines the benefits of quantifying protein-protein interactions (PPI) using automated dynamic light scattering (DLS) in high-throughput screening (HTS) mode to identify promising candidates for drug-like properties and establish the suitability of formulations before entering extended stability studies. The study, which used Wyatt Technology’s DynaPro Plate Reader II high-throughput DLS instrument, was published by GIT Laboratory and may be downloaded at www.wyatt.com/AppNotes/DLS.
Therapeutic monoclonal antibodies (mAbs) are effective at treating chronic diseases such as autoimmune disorders and cancer. Long-term stability is an important attribute of any commercial drug molecule, and of great interest in biotherapeutics in particular. Measurements of PPI indicate colloidal stability, correlate closely to stability and viscosity at high protein concentration, and are widely used as stability-indicating parameters (SIPs) in pre-selecting monoclonal antibody biotherapeutic molecules and formulation conditions before launching the arduous process of long-term stability testing. Ordinarily, PPI studies require significant quantities of sample and labor. Optimal screening processes of PPI will allow drug developers to identify and concentrate development on the most promising mAbs and formulations, saving considerable time and money while decreasing time-to-market.
The study showcases some novel uses of DLS to rapidly provide substantial information about the stability and viscosity of a formulation. Traditionally, PPI are quantified by static light scattering (SLS) as the second virial co-efficient (B22), though recently other techniques have come into widespread use. DLS has proven extremely useful in this field as it provides substantially more information regarding SIPs, with less sample, than standard SLS. DLS quantifies PPI via the diffusion interaction parameter (kD), and Neergaard also explored the relative radius method comparing apparent hydrodynamic radii at low and high concentrations. These methods, using kD and relative radius to quantify PPI in a protein solution, make the process of characterization much quicker and simpler than standard methods.
The DynaPro Plate Reader II is capable of running high-throughput, automated HTS-DLS analyses to characterize PPI in standard microwell plates, under multiple conditions in a significantly reduced time frame, making DLS a viable option for SIP screening. As an added benefit, DLS measures the viscosity of highly concentrated proteins with the same high throughput and low sample consumption. The onset points of aggregation or melting may be obtained in the DynaPro via temperature ramps or chemical denaturing, to assess additional SIPs for conformational stability, making the DynaPro DLS plate reader the ultimate tool for developability and formulation screening.
“Techniques for determining protein stability are still widely debated amongst researchers, and a combination of stability-indicating parameters must be weighed to get a complete picture,” explains Dr Daniel Some, Director of Marketing and Principal Scientist at Wyatt Technology, “Optimization of screening processes to reduce time and resources spent on ensuring long-term viability is a key consideration in the drug development process. The DynaPro Plate Reader II ensures comprehensive testing, over a range of conditions in minimal time, and eliminates the need for additional laboratory apparatus when screening the stability-indicating parameters of high concentration protein formulations.”
Related News
-
News Women in Pharma: Moving beyond discussions and into best practice at CPHI Milan
In this second CPHI Milan special of our monthly series, we cover the key takeaways from the Diversity & Wellbeing track held on October 10, 2024. -
News AstraZeneca invests in AI collaboration for cancer drug trials
The British-Swedish pharmaceutical giant is partnering with biotechnology firm Immunai Inc to increase the efficiency of some cancer drug trials. -
News Ozempic and Wegovy prices questioned as Novo Nordisk faces US Senate hearing
The CEO of Novo Nordisk was grilled during a US Senate committee hearing on September 24, 2024, in which the exorbitant prices of the Danish company’s blockbuster drugs Ozempic and Wegovy were called into question. -
News The BIOSECURE Act: implications for the pharma supply chain
On September 9, 2024, the US House of Representatives voted to pass the bill titled the BIOSECURE Act (the Act), which lists several Chinese companies in the pharmaceutical supply chain. The Act will prohibit American companies from contracting or doin... -
News On Track at CPHI Milan: Thermo Fisher Scientific Track Sponsor interview
With CPHI Milan just around the corner, we sat down with some of the sponsors for this year’s conference tracks to discuss the most pressing topics in pharma. -
News CPHI Milan Speaker Spotlight: Pharma Manufacturing and Localisation in Africa
In the run-up to CPHI Milan, we sit down with some of the experts and thought-leaders speaking at this year’s conferences. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Eli Lilly licenses rheumatoid arthritis manufacturing in Africa
American pharmaceutical company Eli Lilly has signed a partnership with Egyptian organisation Eva Pharma to localise manufacturing of rheumatoid arthritis treatments in Africa.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance